Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Carcinoma, Hepatocellular 13Cholangiocarcinoma 2Pancreatic Neoplasms 1Locally Advanced Thyroid Gland Carcinoma 1Liver Neoplasms 1Hepatocellular Carcinoma with PVTT 1Digestive System Neoplasms 1Differentiated Thyroid Cancer 1Diabetes Mellitus 1Cirrhosis, Familial, with Pulmonary Hypertension 1Carcinoma 1Biliary Tract Adenocarcinoma 1Biliary Malignant Tumors 1

Interventions

surufatinib 1pembrolizumab 1lenvatinib 1donafenib 1Thyrotropin Alfa 1Sorafenib 1Injections 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Differentiated Thyroid Cancer × donafenib × Clear all
NCT02870569 2019-03-01

Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 2 Completed
48 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡